SmithKline Beecham

Executive Summary

Sells A-200 lice treatment product line to Hogil Pharmaceutical, a privately held consumer and pet health care products firm based in Armonk, N.Y. SmithKline did not disclose terms of the deal, which is effective Dec. 31. SmithKline explained in a Dec. 30 press release that its decision to divest A-200, which is marketed in the U.S. and Puerto Rico, is part of the company's strategy to concentrate on its "core OTC brands." Hogil will receive "transitional services" from SmithKline for "up to one year," the release states